Aldeyra Therapeutics, Inc. (ALDX)
- Business Wire
Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
LEXINGTON, Mass., May 18, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today reported that a post-hoc analysis using computer automated grading of digital photography from the completed Phase 3 TRANQUILITY dry eye chamber trial demonstrated statistical significance (p=0.020) in favor of reproxalap over vehicle for the primary endpoint of reduction of ocular redness. As previously announced, the Phase 3 TRANQUILITY trial failed to meet the primary endpoint of ocular redness as assess
- Motley Fool
Aldeyra Therapeutics (ALDX) Q1 2022 Earnings Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Aldeyra Therapeutics first quarter 2022 financial results conference call. With me today are Dr. Todd Brady, president and chief executive officer, and Bruce Greenberg, incoming Interim CFO. This morning, we issued a press release reporting our financial results for the quarter ended March 31, 2022.
- Business Wire
Aldeyra Therapeutics Reports First-Quarter 2022 Financial Results and Recent Corporate Highlights
LEXINGTON, Mass., May 05, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial results for the quarter ended March 31, 2022.
